Allegheny Health Network
Find a
Doctor
Request An Appointment Login to
MyChart
Patient
Center
News Classes &
Events
Contact
Us
Call 412.Doctors

Active Clinical Trials

Sitravatinib and Nivolumab in Urothelial Carcinoma Study

Active NCT:
03606174
Allegheny General Hospital
Allegheny General Hospital

Sponsor: 
Mirati Therapeutics Inc.
Contact: 

For more information, please contact Josh Woolford by telephone at 412-359-3826 or email at Josh.Woolford@ahn.org or Brittany Swinson by telephone at 412-359-6480 or email Brittany.Swinson@ahn.org.

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma

Purpose: 

The study will evaluate the clinical activity of nivolumab in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.

Ages Eligible for Study:  18 Years and older   (Adult, Older Adult)

Sexes Eligible for Study:  All

Accepts Healthy Volunteers:  No

Inclusion Criteria:

Diagnosis of urothelial carcinoma

Most recent treatment must have included a checkpoint inhibitor

Adequate bone marrow and organ function

Exclusion Criteria:

Uncontrolled tumor in the brain

Unacceptable toxicity with prior checkpoint inhibitor

Impaired heart function